La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Design Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Design Therapeutics..

Design Therapeutics (NASDAQ:DSGN) Azioni, Catena delle Opzioni

Design Therapeutics

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Design Therapeutics Inc

<a href="https://www.medtronic.com/en-us/index.html">Medtronic plc</a>, a global leader in health care technology, announced today that the U.S. Department of Veterans Affairs (VA) has awarded a three-year Indefinite Delivery Indefinite Quantity (IDIQ) contract for <a href="https://www.medtronic.com/en-us/healthcare-professionals/products/digestive-gastrointestinal/gastrointestinal-artificial-intelligence/gi-genius-intelligent-endoscopy-module.html">GI Genius</a>&#x2122; AI-powered endoscopy units, resulting in almost 100 additional units being installed across VA medical centers nationwide. This expansion underscores the ability of Medtronic's proven technology to deliver state-of-the-art care to veterans, aiming to provide gold-standard diagnostic accuracy in colorectal screenings for thousands who served.

News

Contracts

Medtronic Awarded 3-Year VA Contract To Expand GI Genius AI Technology To Enhance Colorectal Cancer Detection In Veterans

U.S. stocks traded higher this morning, with the Dow Jones index gaining by more than 300 points on Monday.
Following the market opening Monday, the Dow traded up 0.79% to 44,644.55 while the NASDAQ rose 0.69% to 19,134.73. The S&amp;P 500 also rose, gaining, 0.60% to 6,004.86.
Check This Out: <a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a>
Leading and Lagging Sectors Consumer discretionary shares jumped by 1.6% on Monday.
In trading on Monday, energy shares rose by just 0.3%.
Top Headline
Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) reported better-than-expected third-quarter results and raised its 2024 outlook.
BBWI's third-quarter adjusted earnings per share of 49 cents, beating the analyst consensus of 47 cents. Quarterly sales of $1.610 billion, a growth of 3.1% year-over-year, above the street view of $1.579 billion.
The company raised fiscal 2024 guidance and now expects net sales to decline 2.5% – 1.7% (prior view: decline of 4% – 2%), including a 100-basis-point headwind from the 53rd week in 2023. Adjusted earnings per share are projected at $3.15 – $3.28 (prior view $3.06 – $3.26) versus the $3.18 consensus.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>QMMM Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) shares shot up 115% to $1.61.</li>
<li>Shares of Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) got a boost, surging 52% to $13.83 after jumping 127% on Friday.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares were also up, gaining 54% to $2.6867 after the company completed a $100 million at-the-market equity offering, with plans to use the proceeds for working capital, capital expenditures, and advancements in superconducting quantum computing technology.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) shares dropped 85% to $3.9801 after the company announced Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer&#8217;s disease in the ReThink-ALZ Phase 3 study.</li>
<li>Shares of Oncternal Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) were down 33% to $0.7620 after the company announced that NASDAQ plans to delist its stock.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) was down, falling 29% to $0.51 after the company announced restructuring amidst its bankruptcy and delisting challenges.</li>
</ul>
Commodities In commodity news, oil traded down 1.9% to $69.91 while gold traded down 2.5% at $2,645.60.
Silver traded down 2.8% to $30.46 on Monday, while copper rose 0.8% to $4.1190.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 slipped 0.1%, Germany's DAX gained 0.5% and France's CAC 40 rose 0.1%. Spain's IBEX 35 Index rose 0.8%, while London's FTSE 100 gained 0.3%.
The Ifo Business Climate indicator for Germany fell to 85.7 in November compared to 86.5 in October and down from market expectations of 86. Producer prices in Spain fell by 3.9% year-over-year in October.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 1.30%, Hong Kong's Hang Seng Index falling 0.41%, China's Shanghai Composite Index falling 0.11% and India's BSE Sensex gaining 1.25%.
Economics
The Chicago Fed National Activity Index fell to -0.40 in October compared to -0.27 in the previous month and versus market estimates of -0.20.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42163921/top-3-real-estate-stocks-that-may-explode-in-q4">Top 3 Real Estate Stocks That May Explode In Q4</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Eurozone

Intraday Update

Markets

Trading Ideas

BBWI

CMAX

ONCT

QMCO

QMMM

RGTI

SAVA

Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings

The Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) has shattered records, crossing $100 billion in annual inflows this year, a historic high for any ETF over the same period. 
Data from ETF.com shows that the fund witnessed $101.07 billion in fresh money from investors, more than the combined inflows of its two closest competitors: iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) with $59.2 billion and SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) with just $22.9 billion.&nbsp;
In the multi-trillion-dollar exchange-traded fund industry, this trend is sparking debate over whether SPY, the world's largest ETF, is now on the brink of losing its long-standing crown.
<h3 class="wp-block-heading">$VOO Poised To Become The World&#8217;s Largest ETF Next Year </h3>
Despite SPY still holding the title of the world's largest ETF, with $620 billion in assets under management (AUM), the gap between it and VOO — currently at $579 billion — has narrowed to $41 billion.
&#8220;That means that there is a very real possibility that VOO overtakes SPY as the world's largest ETF as soon as next year,&#8221; commented Sumit Roy, senior analyst at ETF.com. 
&#8220;But even if that happens, SPY's slide down the ETF leaderboard might not stop there. IVV is also nipping at its heels, with $565 billion in AUM,&#8221; he added. 
<h3 class="wp-block-heading">World&#8217;s 10 Largest ETFs by AUM</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>ETF Name</th>
<th>AUM ($ bn)</th>
<th>Expense ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPDR S&amp;P 500 ETF TRUST</td>
<td>620.26</td>
<td>0.09%</td>
</tr>
<tr>
<td>Vanguard S&amp;P 500 ETF</td>
<td>579.35</td>
<td>0.03%</td>
</tr>
<tr>
<td>iShares Core S&amp;P 500 ETF</td>
<td>559.64 </td>
<td>0.03%</td>
</tr>
<tr>
<td>Vanguard Total Stock Market (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>)</td>
<td>460.11</td>
<td>0.03%</td>
</tr>
<tr>
<td>Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)</td>
<td>310.27 </td>
<td>0.20%</td>
</tr>
<tr>
<td>Vanguard Growth ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VUG#NYSE">VUG</a>)</td>
<td>151.13 </td>
<td>0.04%</td>
</tr>
<tr>
<td>Vanguard FTSE Developed Markets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEA#NYSE">VEA</a>)</td>
<td>135.42</td>
<td>0.06%</td>
</tr>
<tr>
<td>Vanguard Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTV#NYSE">VTV</a>)</td>
<td>133.31</td>
<td>0.04%</td>
</tr>
<tr>
<td>Vanguard Total Bond Market (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BND#NYSE">BND</a>)</td>
<td>119.17 </td>
<td>0.03%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: ETF.com</figcaption></figure>
<h3 class="wp-block-heading">Expense Ratio: A Critical Factor For VOO&#8217;s Institutional Inflows</h3>
A key driver of VOO's success is its rock-bottom expense ratio of 0.03%, less than a third of SPY's 0.0945%. 
These differences have significant implications, especially for institutional investors managing billions.
A retail investor putting $5,000 into VOO at the start of the year would pay only $1.50 in annual expenses, while the same investment in SPY would cost $4.73 – basically an irrelevant difference. 
In sharp contrast, an institutional investor allocating $5 billion to VOO would pay just $1.5 million in fees, compared to $4.73 million with SPY—a staggering $3.23 million difference.
This simple example may explain that expense ratio differences are a huge driver of wholesale <a href="https://www.benzinga.com/etfs">investor flows into ETFs</a>.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/24/11/42148340/black-friday-cyber-monday-deals-on-wall-street-why-buying-walmart-or-amazon-before-the-holidays-might-backfire">Why Walmart, Amazon Stock Could Stumble This Holiday Season</a></li>
</ul>
Image:

Analyst Color

Large Cap

Broad U.S. Equity ETFs

ETFs

Vanguard's S&P 500 ETF Hits $100 Billion Inflows In 2024: Is SPY's Crown At Risk?

Revenue grows from $6.7 million to $13.9 million
FUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Shengfeng Development Limited ("Shengfeng" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFWL#NASDAQ">SFWL</a>), a&nbsp;contract logistics company&nbsp;in China&nbsp;providing customers with integrated logistics solutions, announced&nbsp;today a 107.8% year-over-year increase in revenue generated from&nbsp;China Post Group Corporation during the 2024 Double 11 Shopping Festival.
The Double 11 Shopping Festival, also known as the "Singles' Day, is China's largest annual online shopping event, comparable to Black Friday in the United States. Held each year on November 11, the festival has evolved into a major e-commerce event, with consumers nationwide taking advantage of substantial discounts and promotions offered by various retailers. From October 20, 2024 to November 20, 2024, Shengfeng provided postal logistics services to China Post Group Corporation across multiple post offices. This collaboration resulted in an increase in Shengfeng's service volume and revenue. The Company's revenue from these services totaled RMB 100,221,043 (approximately $13.9 million), which was an increase from RMB 48,230,091 (approximately $6.7 million) during the same period in 2023, marking a 107.8% year-over-year growth.

Earnings

SFWL

Shengfeng Development Limited Reports Revenue Grew From $6.7M To $13.9M YoY From China Post Group Corporation During The 2024 Double 11 Shopping Festival

Investors with a lot of money to spend have taken a bullish stance on Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BA, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Boeing.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $102,820, and 7, calls, for a total amount of $570,701.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $125.0 to $160.0 for Boeing over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Boeing's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Boeing's whale trades within a strike price range from $125.0 to $160.0 in the last 30 days. 
<h3>Boeing Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732545934_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$28.3</td>
<td>$26.65</td>
<td>$28.3</td>
<td>$150.00</td>
<td>$141.5K</td>
<td>1.0K</td>
<td align="right">202</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$29.1</td>
<td>$28.1</td>
<td>$28.1</td>
<td>$150.00</td>
<td>$140.5K</td>
<td>1.0K</td>
<td align="right">202</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$11.7</td>
<td>$10.55</td>
<td>$10.6</td>
<td>$160.00</td>
<td>$102.8K</td>
<td>1.9K</td>
<td align="right">129</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$33.85</td>
<td>$33.65</td>
<td>$33.85</td>
<td>$125.00</td>
<td>$84.6K</td>
<td>44</td>
<td align="right">25</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$3.8</td>
<td>$3.75</td>
<td>$3.75</td>
<td>$150.00</td>
<td>$75.0K</td>
<td>2.0K</td>
<td align="right">7</td>
</tr>
</tbody>
</table>

<h3>About Boeing</h3>
Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with Lockheed, Northrop, and several other firms to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
Following our analysis of the options activities associated with Boeing, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Boeing</h3>
<ul>
<li>Currently trading with a volume of 357,062, the BA's price is up by 1.43%, now at $151.43. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 65 days.</li>
</ul>
<h3>What The Experts Say On Boeing</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $161.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $200. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Underweight rating on Boeing with a target price of $85. 
&#x2A; An analyst from Bernstein downgraded its action to Market Perform with a price target of $169. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Boeing, which currently sits at a price target of $190. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Boeing, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Decoding Boeing's Options Activity: What's the Big Picture?

Financial giants have made a conspicuous bearish move on Netflix. Our analysis of options history for Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) revealed 13 unusual trades.
Delving into the details, we found 15% of traders were bullish, while 76% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $109,130, and 10 were calls, valued at $473,290.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $760.0 to $1000.0 for Netflix during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Netflix's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Netflix's significant trades, within a strike price range of $760.0 to $1000.0, over the past month.
<h3>Netflix 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732545929_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$163.15</td>
<td>$157.35</td>
<td>$158.87</td>
<td>$805.00</td>
<td>$158.8K</td>
<td>20</td>
<td align="right">10</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$166.9</td>
<td>$165.0</td>
<td>$165.0</td>
<td>$760.00</td>
<td>$82.5K</td>
<td>306</td>
<td align="right">0</td>
</tr>
<tr>
<td>NFLX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$13.85</td>
<td>$10.95</td>
<td>$13.0</td>
<td>$890.00</td>
<td>$41.3K</td>
<td>709</td>
<td align="right">419</td>
</tr>
<tr>
<td>NFLX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$39.25</td>
<td>$36.8</td>
<td>$39.25</td>
<td>$900.00</td>
<td>$39.2K</td>
<td>325</td>
<td align="right">10</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$2.39</td>
<td>$2.33</td>
<td>$2.37</td>
<td>$915.00</td>
<td>$38.6K</td>
<td>1.5K</td>
<td align="right">632</td>
</tr>
</tbody>
</table>

<h3>About Netflix</h3>
Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 280 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm recently began introducing ad-supported subscription plans, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
Following our analysis of the options activities associated with Netflix, we pivot to a closer look at the company's own performance.
<h3>Where Is Netflix Standing Right Now?</h3>
<ul>
<li>With a volume of 71,159, the price of NFLX is up 0.27% at $900.2. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 57 days.</li>
</ul>
<h3>Expert Opinions on Netflix</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $968.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $950. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Netflix, maintaining a target price of $1000. 
&#x2A; Consistent in their evaluation, an analyst from Pivotal Research keeps a Buy rating on Netflix with a target price of $1100. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Netflix, which currently sits at a price target of $825. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Netflix with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

NFLX

Market Whales and Their Recent Bets on NFLX Options

BTIG analyst Andre Madrid initiates coverage on V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) with a Buy rating and announces Price Target of $80.

Price Target

Initiation

Analyst Ratings

BTIG Initiates Coverage On V2X with Buy Rating, Announces Price Target of $80

Financial giants have made a conspicuous bearish move on Nano Nuclear Energy. Our analysis of options history for Nano Nuclear Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) revealed 12 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $98,615, and 9 were calls, valued at $575,750.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $45.0 for Nano Nuclear Energy, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Nano Nuclear Energy's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Nano Nuclear Energy's whale trades within a strike price range from $25.0 to $45.0 in the last 30 days. 
<h3>Nano Nuclear Energy 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732545924_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$7.0</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$40.00</td>
<td>$91.6K</td>
<td>0</td>
<td align="right">141</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.0</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$40.00</td>
<td>$90.0K</td>
<td>4</td>
<td align="right">551</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$10.7</td>
<td>$7.5</td>
<td>$9.0</td>
<td>$25.00</td>
<td>$90.0K</td>
<td>246</td>
<td align="right">100</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.4</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$30.00</td>
<td>$77.1K</td>
<td>1.4K</td>
<td align="right">511</td>
</tr>
<tr>
<td>NNE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$4.1</td>
<td>$3.7</td>
<td>$3.8</td>
<td>$25.00</td>
<td>$76.0K</td>
<td>548</td>
<td align="right">4</td>
</tr>
</tbody>
</table>

<h3>About Nano Nuclear Energy</h3>
Nano Nuclear Energy Inc is an early-stage nuclear energy company developing smaller, cheaper, and safer advanced portable clean energy solutions. It is focused on four business lines as part of development: Micro Nuclear Reactor Business is developing the next-generation nuclear microreactors, in particular ZEUS, a solid core battery reactor, and ODIN, a low-pressure salt coolant reactor. Fuel Fabrication Business, Fuel Transportation Business and Nuclear Consultation Services.
Following our analysis of the options activities associated with Nano Nuclear Energy, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Nano Nuclear Energy</h3>
<ul>
<li>With a trading volume of 1,309,803, the price of NNE is down by -11.11%, reaching $29.87.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 11 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Nano Nuclear Energy</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $58.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $50. 
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on Nano Nuclear Energy, which currently sits at a price target of $66. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Nano Nuclear Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

What the Options Market Tells Us About Nano Nuclear Energy

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Loop Capital cut the price target for Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from $38 to $35. Loop Capital analyst Alan Gould maintained a Hold rating. Warner Music shares closed at $31.85 on Friday. <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised the price target for Helen of Troy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) from $71 to $78. DA Davidson analyst Linda Bolton Weiser maintained a Neutral rating. Helen of Troy shares closed at $69.92 on Friday. <a href="https://www.benzinga.com/quote/HELE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen boosted Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $475 to $515. TD Cowen analyst Andrew Charles maintained a Buy rating. Domino&#8217;s shares settled at $453.35 on Friday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity boosted MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) price target from $300 to $510. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. MicroStrategy shares closed at $421.88 on Friday. <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) price target from $55 to $75. B of A Securities analyst Mariana Perez maintained a Buy rating. Palantir shares closed at $64.35 on Friday.  <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Wix.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) price target from $175 to $215. Baird maintained a Neutral rating on the stock. Wix shares closed at $217.20 on Friday. See how other analysts view this stock.</li>
<li>Wells Fargo cut the price target for HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) from $400 to $320. Wells Fargo analyst Stephen Baxter downgraded the stock from Equal-Weight to Underweight. HCA Healthcare shares settled at $324.93 on Friday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup boosted U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) price target from $49 to $65. Citigroup analyst Keith Horowitz upgraded the stock from Neutral to Buy. U.S. Bancorp shares closed at $52.49 on Friday. <a href="https://www.benzinga.com/quote/USB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush increased the price target for Salesforce, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from $325 to $375. Wedbush analyst Daniel Ives maintained an Outperform rating. Salesforce shares closed at $342.02 on Friday. <a href="https://www.benzinga.com/quote/CRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson boosted The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) price target from $160 to $209. DA Davidson analyst Linda Bolton Weiser upgraded the stock from Neutral to Buy. Procter &amp; Gamble shares closed at $176.28 on Friday. <a href="https://www.benzinga.com/quote/PG/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

HELE

MSTR

PLTR

Salesforce To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday

Following the announcement of <a href="https://www.benzinga.com/startups/24/11/42068770/the-most-influential-kennedy-in-decades-heres-how-much-robert-f-kennedy-jr-is-really-worth">Robert F. Kennedy Jr.</a> as President-elect Donald Trump's pick for Secretary of Health and Human Services (HHS), many have raised concerns about the future of public health policy.&nbsp;
Don't Miss:
<ul>
<li>Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>
However, CNBC's <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41798981/jim-cramer-calls-trumps-return-to-white-house-a-huge-win-for-the-stock-market">Jim Cramer</a> stated that even with Kennedy's controversial stances potentially undoing "some of the biggest public health advances of the last century," the pharmaceutical and processed food industries likely won't see drastic disruptions.&nbsp;
The HHS is a large federal agency with a $1.7 trillion budget and over 80,000 employees. It oversees programs like Medicare, Medicaid and the Free Vaccines for Children Program and manages agencies such as the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH).&nbsp;
Kennedy, a vaccine skeptic and critic of processed foods, desires to reshape public health policy. Critics, including Cramer, argue his views could roll back scientific advancements in vaccines and nutrition. Kennedy has voiced his intent to address what he calls a "broken" food system and has proposed unconventional approaches, such as substituting weight-loss drugs with subsidized gym memberships and organic food for <a href="https://www.benzinga.com/general/biotech/24/10/41257459/biden-administration-unveils-plan-to-provide-generic-drugs-for-2-to-medicare-recipients">Medicaid recipients</a>.
See Also: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
Despite Kennedy's ambitions, Cramer is skeptical about their impact. While speaking on Mad Money, he said, "The interests within the government, notably the staff, will push back and the food lobby will push back. And, most important, Americans just don't like being told what to do."
Cramer believes the cultural resistance, paired with the influence of government staff and lobbyists, will ultimately limit Kennedy's ability to make sweeping changes.&nbsp;
Cramer also emphasized that industries like pharmaceuticals and processed foods are deeply entrenched in U.S. systems and have significant lobbying power. Previous attempts to curtail processed foods or radically shift public health narratives often face resistance from the public and policymakers.&nbsp;
Trending: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Stock prices for companies like Eli Lilly, Moderna, PepsiCo and General Mills declined after Kennedy's nomination. However, Cramer argues that these industries are resilient and have <a href="https://www.benzinga.com/markets/24/10/41124658/diversification-for-idiots-valuation-guru-challenges-charlie-mungers-thoughts-on-putting-all-your-eg">diversified portfolios</a> that extend beyond vaccines or specific food products.&nbsp;
Processed food companies, backed by strong lobbying efforts, have historically fended off major regulatory changes. While Kennedy's focus on nutrition may gain bipartisan support, Cramer states that achieving substantial reforms would require navigating the complex web of political and economic interests supporting the current food system.&nbsp;
Ultimately, Cramer – known for his investment advice on Mad Money – said that while he doesn't see the drug and food industries taking a huge hit with Kennedy at the helm, he's not recommending investors purchase these stocks.&nbsp;
"For now, nobody wants to take a chance on these already out-of-favor industries," Cramer said. "And, you know what, I can't blame them," he said.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

'Americans Just Don't Like Being Told What To Do,' Jim Cramer Weighs, Stating Why RFK Running HHS Won't Kill Pharma And Food Giants

Barclays analyst Mathieu Robilliard maintains Telefonica Brasil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIV#NYSE">VIV</a>) with a Equal-Weight and raises the price target from $11.5 to $11.8.

Barclays Maintains Equal-Weight on Telefonica Brasil, Raises Price Target to $11.8

PDYN

Palladyne AI Shares Resume Trade

Benchmark analyst Mike Hickey maintains Marcus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) with a Buy and raises the price target from $22 to $25.

Benchmark Maintains Buy on Marcus, Raises Price Target to $25

Barclays analyst Luke Sergott maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Overweight and lowers the price target from $140 to $135.

RVTY

Barclays Maintains Overweight on Revvity, Lowers Price Target to $135

QMMM Shares Resume Trade

Barclays analyst Ramsey El-Assal maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Overweight and raises the price target from $275 to $515.

Barclays Maintains Overweight on MicroStrategy, Raises Price Target to $515

Palladyne AI Shares Halted To The Downside; Stock Now Up 9.78%

Barclays analyst Maurice Patrick maintains Liberty Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYA#NASDAQ">LBTYA</a>) with a Equal-Weight and lowers the price target from $20 to $12.

LBTYA

Barclays Maintains Equal-Weight on Liberty Global, Lowers Price Target to $12

QMMM Shares Halted On Circuit Breaker To The Upside, Stock Now Up 114.7%

Barclays analyst Jiong Shao maintains KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) with a Overweight and raises the price target from $30 to $33.

BEKE

Barclays Maintains Overweight on KE Holdings, Raises Price Target to $33

Larimar stock rallies 24% on FDA removal of partial clinical hold

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. However it entails a lot of risk. The Piper Sandler (NYSE:<a href="https://investorplace.com/stock-quotes/pipr-stock-quote/">PIPR</a>) investment firm says it found three biotech stocks with the winning ticket. These Piper Sandler stocks have investors curious. 



Piper Sandler may be the best bet for investors especially when you see where things are for biotech companies. The breakthrough drug discovery process can fail miserably. According to the American Society for Biochemistry and Molecular Biology, <a href="https://www.asbmb.org/asbmb-today/opinions/031222/90-of-drugs-fail-clinical-trials#:~:text=It%20takes%2010%20to%2015,candidates%20in%20clinical%20trials%20fail.">90% of all drug candidates</a> in clinical trials fail. Ouch!



Despite spending $1 billion on average, and waiting 10 to 15 years, most biotechs come up with nothing. That&rsquo;s why when they do succeed it is like hitting the lottery, because they have.



Piper Sandler believes they can post triple-digit returns over the next year. These Piper Sandler stocks are expected to grow by at least 100% in the next 12 months. Let&rsquo;s see why they feel confident these Piper Sandler stocks will double in price.



<h2>Piper Sandler Stocks to Buy: Context Therapeutics (CNTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/orthopedic-therapy-1600-imac-300x169.png" alt="Physiotherapist doing healing treatment on patient leg. Therapist wearing blue uniform. Osteopathy, Chiropractic leg adjustment. Orthopedic therapy. ATIP stck."><div>Source: Microgen / Shutterstock</div></div>Context Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cntx-stock-quote/">CNTX</a>) is already off to the races. The biotech is up 80% so far in 2024 and has more than tripled over the past 12 months. Piper Sandler analyst Joseph Catanzaro initiated coverage of the stock last week with an overweight rating and set a market-high $4.50 per share one-year target price. Context stock currently trades around $2 per share, indicating 125% upside potential.



The analyst highlighted the potential of Context Therapeutics&rsquo; lead drug candidate, CTIM-76, which targets Claudin6 (CLDN6) in solid tumors. CLDN6 is one of the 27 family members of claudins that play an important role in tight adherence epithelial cell sheets that plays a significant role in cancer start and progression.



According to Investing.com CTIM-76 shows indications it <a href="https://www.investing.com/news/company-news/piper-sandler-bullish-on-context-therapeutics-stock-cites-ctim76-program-93CH-3443404">could be effective against</a> a broad range of CLDN6 expressions. That might let it be an effective therapy against different types of cancer, including ovarian and non-small cell lung cancer. Piper Sandler was bullish about the treatment&rsquo;s prospects heading into clinical testing.



Of course, Context Therapeutics is a pre-revenue stage company so its stock is going to be volatile but the market is backing this stock today.



<h2>Revance Therapeutics (RVNC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/health-medical-heart-1600-300x169.jpg" alt="hands holding a red heart shape against blue background symbolizing health"><div>Source: shutterstock.com/Anastasia Zagoruyko</div></div>Analyst David Amsellem reiterated his overweight rating of Revance Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvnc-stock-quote/">RVNC</a>) though he lowered the one-year price target from $20 per share to $11 per share. That is still a 263% implied upside in the stock price.



Unlike Context Therapeutics, Revance does generate revenue from the sale of Daxxify, an alternative to the better known Botox made by AbbVie (NYSE:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>). The treatment lasts between six months and nine months whereas Botox averages three to four months.



First-quarter <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000147929024000099/rvnc-20240509.htm">revenue jumped 13%</a> to $51.9 million on higher Daxxify sales, which hit $22 million. Botox generates about $2 billion annually for AbbVie. Revance generated $29 million in sales of its RHA Collection, or Resilient Hyaluronic Acid, the only hyaluronic acid filler approved by the FDA for dynamic facial lines, wrinkles and folds. Daxxify is now also FDA-approved for the treatment of adults with cervical dystonia, a painful condition that causes the neck muscles to contract involuntarily, which causes the head to twist or turn to one side.



However, Revance stock has been on a long slide lower. Shares are down 65% in 2024 and over 90% for the past year. The stock collapsed after Revance posted bigger than expected losses last year and then continued falling after the biotech said it was <a href="https://www.investors.com/news/technology/rvnc-stock-collapses-as-prestige-plan-goes-up-in-smoke/">cutting prices on Daxxify</a> to better compete against Botox. It likely plays into why the Piper Sandler analyst nearly halved his price target.



<h2>Design Therapeutics (DSGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a-300x169.jpg" alt="stethoscope on a stock chart representing healthcare stocks to buy. Healthcare Stocks"><div>Source: Shutterstock</div></div>Design Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsgn-stock-quote/">DSGN</a>) went the other way when analyst Yasmeen Rahimi doubled her price target from $6 per share to $12 per share. She also upgraded her rating from neutral to overweight. Rahimi says the biotech has a diversified and innovative pipeline that provides a solid foundation for future growth.&nbsp;Trading at around $4.50 per share, the price target implies 167% growth ahead.



The analyst maintains the stock is value-priced yet offers solid financials and sufficient cash on hand to finance its drug development program. She believes the outlook for that program is positive, with promising outcomes for its DT-216P2, DT-168, and the upcoming drug candidates for Huntington&rsquo;s disease and myotonic dystrophy 1.



&#8203;&#8203;DT-216P2 is for the treatment of Friedreich Ataxia, a hereditary disorder that affects some of the body&rsquo;s nerves. DT-168 is for Fuchs endothelial corneal dystrophy, an eye disease that attacks the endothelial layer of the cornea.



Shares of Design Therapeutics are up 69% in 2024.



On the date of publication, Rich Duprey held a LONG position in ABBV stock. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/the-100-club-piper-sandlers-3-top-picks-for-triple-digit-gains/">The 100%+ Club: Piper Sandler&#8217;s 3 Top Picks for Triple-Digit Gains</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Lexeo stock drops 24% amid Friedreich Ataxia study results

Design Therapeutics GAAP EPS of -$0.21

RBC Capital analyst Leonid Timashev maintained a Hold rating on Design Therapeutics (DSGN – Research Report) yesterday and set a price target of $4...

RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)

Leerink Partners analyst Joseph Schwartz has reiterated their neutral stance on DSGN stock, giving a Hold rating on August 5. Joseph Schwartz has g...

Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress

RBC Capital Remains a Hold on Design Therapeutics (DSGN)

Design Therapeutics GAAP EPS of -$0.23 beats by $0.02

Leerink Partners analyst Joseph Schwartz reiterated a Hold rating on Design Therapeutics (DSGN – Research Report) on November 7 and set a price tar...

Comments

Design Therapeutics

Design Therapeutics (DSGN) Opzioni

Design Therapeutics (NASDAQ:DSGN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO